Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema

Efficient Treatments for ACE-I and ARB-induced Angioedema Exist and Should be Available to All Patients. Analysis of Their Availability and Influencing Factors in the Area Around Lyon, France

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02826356

Enrollment

Registered

2016-07-11

Start date

2016-02-29

Completion date

2016-03-31

Last updated

2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACE-I and ARB-induced Angioedema.

Keywords

Angioedema, Emergency treatment, Treatment availability, Health Equity

Brief summary

Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Every patient followed for the first time in our reference center for severe confirmed ACE-I or ARB-induced angioedema. Data were analyzed from patients attended either in a specialized angioedema consultation or during a hospitalization in our intensive care unit. * Severe attack was defined either by its localization over the shoulder or by an severe abdominal attack.

Exclusion criteria

\- Patients which received no specific treatment (icatibant, C1-inhibitor concentrate) were excluded.

Design outcomes

Primary

Measure	Time frame	Description
Step of the care allowing the patients to benefit from a specific treatment.	October 2010 to December 2014	Three answers are possible. Patients were treated with the specific medication (icatibant or C1-inhibitor concentrate) either in the first ED or by the medical ambulance team, or by the investigators reference center's intensive care unit.

Secondary

Measure	Time frame	Description
Epidemiological characteristics	October 2010 to December 2014	The investigators collect data such as age, sex, localization of the angioedema.
Triggering treatments	October 2010 to December 2014	The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema.

Countries

France

Outcome results